Clinical Perspectives and Targeted Therapies in Apoptosis: Drug Discovery, Drug Delivery, and Disease Prevention

Dr. Rupinder K Sodhi’s core areas of research cover different segments of neuropharmacology like cognition, dementia and Alzheimer’s disease. Central to her research activities involves evaluation of the potential of new chemical entities using advanced in vitro and in vivo tools and techniques. More over her expertise is in the field of neurodegenerative and neuropsychiatric disorders like Alzheimer, depression and also in diabetes and related complications such as neuropathic pain, nephropathy pain and inflammation aiming to deconvolute the novel target sites for drug discovery and development. Currently she is active in evaluating the therapeutic efficacy of controlled and targeted drug delivery systems such as nanomedicine in collaboration with pharmaceutics department.

Dr. Jitender Madan’s major areas of research include self-assembled supramolecular systems - liposomes, niosomes, cyclodextrin, nano- and micro-particles and solid-lipid nanoparticles. His focus is on the exploitation of US FDA approved biomaterials in combination with other potential lipids and polymers to develop the innovative dosage forms and drug delivery systems in order to improve the bioavailability, stability, safety (tolerance) and patient-compliance. While a wide range of applications are being considered, special emphasis has been given to augment the aqueous solubility and bioavailability of anticancer drugs as well as on the design, synthesis and development of ligand conjugated stealth nanoconstructs for delivery and targeting of anticancer drugs in cancer cells both in vitro and in vivo.